About Michael
Michael Buchman leads Motley Rice’s antitrust team. He has served as lead or co-lead counsel for a variety of plaintiff clients, including a Fortune 500 company, a foreign government, multiple states, a city and individual consumers in complex antitrust cases concerning restraint of trade, price-fixing, monopolization and other anticompetitive conduct.His more than 25 years of antitrust experience includes playing an active role in some of the largest antitrust class actions in the history of the Sherman Act, including In re NASDAQ Market-Makers Antitrust Litigation ($1.027b settlement)*. Michael represented the largest retailer class representative in the $5.5 billion* In re Payment Card Interchange Fee and Merchant Discount Antitrust Litigation, MDL 1720.* Over the past 20 years, he has been a leader investigating and developing generic drug antitrust class actions. Michael is one of a limited group of plaintiffs’ antitrust class action lawyers who has served as lead trial counsel and tried a generic drug antitrust case. Some of the generic drug antitrust class actions he has been involved with include:MOTLEY RICE CASES:In re Loestrin Antitrust Litigation ($62.5 million settlement in 2020)*In re Aggrenox Antitrust Litigation ($54 million settlement in 2018)*In re Solodyn Antitrust Litigation ($43 million settlement in 2018)*PRIOR TO MOTLEY RICE:In re Wellbutrin SR Antitrust Litigation ($21.5million settlement in 2013)*In re Flonase Antitrust Litigation ($46 million settlement in 2012)* In re Metoprolol Succinate End-Payor Antitrust Litigation ($21 million settlement in 2011)* In re Relafen Antitrust Litigation ($75 million settlement in 2004)*In re Augmentin Antitrust Litigation ($29 million settlement in 2004)* In re Buspirone Antitrust Litigation ($90 million settlement in 2003)*Additional cases he’s actively involved in at Motley Rice include In re Actos Antitrust Litigation, In re Effexor Antitrust Litigation, In re Lipitor Antitrust Litigation, In re Niaspan Antitrust Litigation, In re Suboxone Antitrust Litigation, and In re Zetia Antitrust Litigation.He also has experience litigating aviation matters, including a large antitrust dispute between carriers.Michael completed the National Institute for Trial Advocacy National Trial Training program and has authored and co-authored articles on procedure and competition law.He has been active in his communities serving as pro bono counsel in actions involving the misappropriation of perpetual care monies and as a youth ice hockey coach at Chelsea Piers.Prior to joining Motley Rice, Michael served as an Assistant Attorney General in the New York State Attorney General’s Office, Antitrust Bureau and as co-managing partner of the antitrust department at another large class action law firm in NYC.* Prior results do not guarantee a similar outcome.
Michael Buchman leads Motley Rice’s antitrust team. He has served as lead or co-lead counsel for a variety of plaintiff clients, including a Fortune 500 company, a foreign government, multiple states, a city and individual consumers in complex antitrust cases concerning restraint of trade, price-fixing, monopolization and other anticompetitive conduct.His more than 25 years of antitrust experience includes playing an active role in some of the largest antitrust class actions in the history of the Sherman Act, including In re NASDAQ Market-Makers Antitrust Litigation ($1.027b settlement)*. Michael represented the largest retailer class representative in the $5.5 billion* In re Payment Card Interchange Fee and Merchant Discount Antitrust Litigation, MDL 1720.* Over the past 20 years, he has been a leader investigating and developing generic drug antitrust class actions. Michael is one of a limited group of plaintiffs’ antitrust class action lawyers who has served as lead trial counsel and tried a generic drug antitrust case. Some of the generic drug antitrust class actions he has been involved with include:MOTLEY RICE CASES:In re Loestrin Antitrust Litigation ($62.5 million settlement in 2020)*In re Aggrenox Antitrust Litigation ($54 million settlement in 2018)*In re Solodyn Antitrust Litigation ($43 million settlement in 2018)*PRIOR TO MOTLEY RICE:In re Wellbutrin SR Antitrust Litigation ($21.5million settlement in 2013)*In re Flonase Antitrust Litigation ($46 million settlement in 2012)* In re Metoprolol Succinate End-Payor Antitrust Litigation ($21 million settlement in 2011)* In re Relafen Antitrust Litigation ($75 million settlement in 2004)*In re Augmentin Antitrust Litigation ($29 million settlement in 2004)* In re Buspirone Antitrust Litigation ($90 million settlement in 2003)*Additional cases he’s actively involved in at Motley Rice include In re Actos Antitrust Litigation, In re Effexor Antitrust Litigation, In re Lipitor Antitrust Litigation, In re Niaspan Antitrust Litigation, In re Suboxone Antitrust Litigation, and In re Zetia Antitrust Litigation.He also has experience litigating aviation matters, including a large antitrust dispute between carriers.Michael completed the National Institute for Trial Advocacy National Trial Training program and has authored and co-authored articles on procedure and competition law.He has been active in his communities serving as pro bono counsel in actions involving the misappropriation of perpetual care monies and as a youth ice hockey coach at Chelsea Piers.Prior to joining Motley Rice, Michael served as an Assistant Attorney General in the New York State Attorney General’s Office, Antitrust Bureau and as co-managing partner of the antitrust department at another large class action law firm in NYC.* Prior results do not guarantee a similar outcome.
Michael Buchman leads Motley Rice’s antitrust team. He has served as lead or co-lead counsel for a variety of plaintiff clients, including a Fortune 500 company, a foreign government, multiple states, a city and individual consumers in complex antitrust cases concerning restraint of trade, price-fixing, monopolization and other anticompetitive conduct.
His more than 25 years of antitrust experience includes playing an active role in some of the largest antitrust class actions in the history of the Sherman Act, including In re NASDAQ Market-Makers Antitrust Litigation ($1.027b settlement)*. Michael represented the largest retailer class representative in the $5.5 billion* In re Payment Card Interchange Fee and Merchant Discount Antitrust Litigation, MDL 1720.* Over the past 20 years, he has been a leader investigating and developing generic drug antitrust class actions. Michael is one of a limited group of plaintiffs’ antitrust class action lawyers who has served as lead trial counsel and tried a generic drug antitrust case. Some of the generic drug antitrust class actions he has been involved with include:MOTLEY RICE CASES:In re Loestrin Antitrust Litigation ($62.5 million settlement in 2020)*In re Aggrenox Antitrust Litigation ($54 million settlement in 2018)*In re Solodyn Antitrust Litigation ($43 million settlement in 2018)*
PRIOR TO MOTLEY RICE:In re Wellbutrin SR Antitrust Litigation ($21.5million settlement in 2013)*In re Flonase Antitrust Litigation ($46 million settlement in 2012)* In re Metoprolol Succinate End-Payor Antitrust Litigation ($21 million settlement in 2011)* In re Relafen Antitrust Litigation ($75 million settlement in 2004)*In re Augmentin Antitrust Litigation ($29 million settlement in 2004)* In re Buspirone Antitrust Litigation ($90 million settlement in 2003)*
Additional cases he’s actively involved in at Motley Rice include In re Actos Antitrust Litigation, In re Effexor Antitrust Litigation, In re Lipitor Antitrust Litigation, In re Niaspan Antitrust Litigation, In re Suboxone Antitrust Litigation, and In re Zetia Antitrust Litigation.
He also has experience litigating aviation matters, including a large antitrust dispute between carriers.
Michael completed the National Institute for Trial Advocacy National Trial Training program and has authored and co-authored articles on procedure and competition law.
He has been active in his communities serving as pro bono counsel in actions involving the misappropriation of perpetual care monies and as a youth ice hockey coach at Chelsea Piers.
Prior to joining Motley Rice, Michael served as an Assistant Attorney General in the New York State Attorney General’s Office, Antitrust Bureau and as co-managing partner of the antitrust department at another large class action law firm in NYC.
* Prior results do not guarantee a similar outcome.
